Guilt by association: ILD genetics and co-morbidities最新文献

英文中文

S143 Serum CYFRA 21–1 as a prognostic marker in scleroderma-associated interstitial lung disease 血清CYFRA 21-1作为硬皮病相关间质性肺疾病的预后标志物

Guilt by association: ILD genetics and co-morbidities

Pub Date : 2018-12-01 DOI: 10.1136/THORAX-2018-212555.149

C. Stock, R. Hoyles, C. Daccord, M. Kokosi, V. Alfieri, C. Campochiaro, J. Donovan, L. Mori, T. Maher, V. Kouranos, G. Margaritopoulos, P. George, P. Molyneaux, F. Chua, D. Abraham, V. Ong, C. Denton, A. Wells, E. Renzoni

Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). The progression of SSc associated ILD (SSc-ILD) is highly variable. Markers predictive of progressive ILD are needed early in the disease course, to appropriately target patients at risk of developing progressive pulmonary fibrosis. CYFRA 21–1 (CYFRA) is a tumour marker expressed by type I/type II pneumocytes and respiratory bronchiolar epithelial cells, released into the blood following cell lysis. Serum levels of CYFRA were measured in both a retrospective (n=180) and a prospective (n=118) cohort of SSc patients. Retrospective cohort mean age: 49.1 (range 47.08–51.05), 77.25% female, prospective cohort age: 56.4 (54.10–58.73), 76.23% female. Median FVC% predicted and DLCO% predicted: retrospective cohort: 80.1% (IQR:67.2–95.5) and 55.5% (44.3–68.35), respectively – prospective cohort: 73.8% (57.2–87) and 39.9% (29.2–48.8), respectively. ILD was defined as the presence of fibrosis on chest imaging (chest x-ray or HRCT) and/or a forced vital capacity (FVC)

间质性肺疾病(ILD)是系统性硬化症(SSc)的主要死亡原因。SSc相关ILD (SSc-ILD)的进展是高度可变的。在病程早期需要预测进行性ILD的标志物，以适当地靶向有发展为进行性肺纤维化风险的患者。CYFRA 21-1 (CYFRA)是一种肿瘤标志物，由I/ II型肺细胞和呼吸细支气管上皮细胞表达，在细胞裂解后释放到血液中。在回顾性(n=180)和前瞻性(n=118) SSc患者队列中测量血清CYFRA水平。回顾性队列平均年龄:49.1岁(47.08-51.05)，女性77.25%;前瞻性队列平均年龄:56.4岁(54.10-58.73)，女性76.23%。预测FVC%和DLCO%的中位数:回顾性队列分别为80.1% (IQR: 67.2-95.5)和55.5%(44.3-68.35)，前瞻性队列分别为73.8%(57.2-87)和39.9%(29.2-48.8)。ILD定义为胸部影像学(胸部x线或HRCT)和/或用力肺活量(FVC)出现纤维化。

{"title":"S143 Serum CYFRA 21–1 as a prognostic marker in scleroderma-associated interstitial lung disease","authors":"C. Stock, R. Hoyles, C. Daccord, M. Kokosi, V. Alfieri, C. Campochiaro, J. Donovan, L. Mori, T. Maher, V. Kouranos, G. Margaritopoulos, P. George, P. Molyneaux, F. Chua, D. Abraham, V. Ong, C. Denton, A. Wells, E. Renzoni","doi":"10.1136/THORAX-2018-212555.149","DOIUrl":"https://doi.org/10.1136/THORAX-2018-212555.149","url":null,"abstract":"Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). The progression of SSc associated ILD (SSc-ILD) is highly variable. Markers predictive of progressive ILD are needed early in the disease course, to appropriately target patients at risk of developing progressive pulmonary fibrosis. CYFRA 21–1 (CYFRA) is a tumour marker expressed by type I/type II pneumocytes and respiratory bronchiolar epithelial cells, released into the blood following cell lysis. Serum levels of CYFRA were measured in both a retrospective (n=180) and a prospective (n=118) cohort of SSc patients. Retrospective cohort mean age: 49.1 (range 47.08–51.05), 77.25% female, prospective cohort age: 56.4 (54.10–58.73), 76.23% female. Median FVC% predicted and DLCO% predicted: retrospective cohort: 80.1% (IQR:67.2–95.5) and 55.5% (44.3–68.35), respectively – prospective cohort: 73.8% (57.2–87) and 39.9% (29.2–48.8), respectively. ILD was defined as the presence of fibrosis on chest imaging (chest x-ray or HRCT) and/or a forced vital capacity (FVC)","PeriodicalId":164956,"journal":{"name":"Guilt by association: ILD genetics and co-morbidities","volume":"123 5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128368061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Guilt by association: ILD genetics and co-morbidities

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀